The vector of anti-NY-ESO-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human NY-ESO-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-NY-ESO-1 antibody linked to CD28 transmembrane domain/ endodomain and FcεRIγ signaling domains. And the vector product was designed for the treatment of metastatic melanoma and synovial cell sarcoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|VP-TCR-C069||Lenti-NY-ESO-1 T cell receptor (TCRCD4-NY#16) Viral Particle|
|VP-CAR-LC190||Lenti-NY-ESO-1 CAR (scFv-b2c-CD3ζ, ES121) Viral Particle|
|TCR-L151||Human anti-NY-ESO-1 T cell receptor (TCRCD8-NY#2), pCDTCR1|
|VP-TCR-C073||Lenti-NY-ESO-1 T cell receptor (5B8) Viral Particle|
|TCR-L162||Human anti-NY-ESO-1 T cell receptor (TCRCD4-NY#10), pCDTCR1|
|TCR-L158||Human anti-NY-ESO-1 T cell receptor (TCRCD4-NY#1), pCDTCR1|
|VP-CAR-LC184||Lenti-NY-ESO-1 CAR (scFv-CD28-FcεRIγ, ES121) Viral Particle|
|VP-TCR-C072||Lenti-NY-ESO-1 T cell receptor (SB95) Viral Particle|
|VP-TCR-C063||Lenti-NY-ESO-1 T cell receptor (TCRCD4-NY#3) Viral Particle|
|TCR-L163||Human anti-NY-ESO-1 T cell receptor (TCRCD4-NY#11), pCDTCR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved